Purespring Therapeutics
Biotech · London, GB
Gene therapies for kidney diseases via AAV platform targeting podocytes.
Funding history
| Date | Round | Amount |
|---|
| Oct 2024 | Series B London gene-therapy startup Purespring Therapeutics raised an £80M Series B led by Sofinnova Partners to advance its kidney-disease pipeline. | $104M |
Investors
British Patient CapitalForbionGilde HealthcareSofinnova PartnersSyncona
Similar companies in Biotech
Explore funding flow on EquityFlow →